Towards an Immunotherapy for p185HER2 Overexpressing Tumors
- 1 January 1994
- book chapter
- Published by Springer Nature
- Vol. 353, 83-94
- https://doi.org/10.1007/978-1-4615-2443-4_9
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal AntibodyJapanese Journal of Cancer Research, 1992
- Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unitCell, 1992
- Isolation of the NeuHER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cellsCell, 1992
- By-passing immunizationJournal of Molecular Biology, 1991
- Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinicJournal of Clinical Immunology, 1991
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990
- Direct Interaction of a Ligand for the erb B2 Oncogene Product with the EGF Receptor and p185
erb
B2
Science, 1990
- Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.The Journal of Experimental Medicine, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986